| Literature DB >> 29803319 |
Matteo Floris1, Stefania Olla2, David Schlessinger3, Francesco Cucca4.
Abstract
Choosing the right biological target is the critical primary decision for the development of new drugs. Systematic genetic association testing of both human diseases and quantitative traits, along with resultant findings of coincident associations between them, is becoming a powerful approach to infer drug targetable candidates and generate in vitro tests to identify compounds that can modulate them therapeutically. Here, we discuss opportunities and challenges, and infer criteria for the optimal use of genetic findings in the drug discovery pipeline.Entities:
Keywords: coincident genetic associations; drug discovery; druggability; quantitative phenotypes; therapeutic targets
Mesh:
Year: 2018 PMID: 29803319 PMCID: PMC6088790 DOI: 10.1016/j.tig.2018.04.004
Source DB: PubMed Journal: Trends Genet ISSN: 0168-9525 Impact factor: 11.639